Abstract: The present invention relates to new compounds of formula (I) that show great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), or dual activity towards the subunit ?2? of voltage-gated calcium channels (VGCC) and the noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to new compounds of general formula (I) that show dual activity towards subunit ?2? of voltage-gated calcium channels (VGCC), especially ?2?-1 subunit of voltage-gated calcium channels, and noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions composing them, and to their use as medicaments.

Abstract: The present invention relates to new compounds of formula (I) that show great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels or dual activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to new compounds of formula (I) that show great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels or dual activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to new compounds of formula (I) that show great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), or dual activity towards the subunit ?2? of voltage-gated calcium channels (VGCC) and the noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to new compounds of general formula (I) showing great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels or dual activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels, and the ?-opioid receptor (MOR or mu-opioid receptor). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to 2-phenyl-2H-pyrazolo[3,4-d]pyridazine derivatives having pharmacological activity towards the ?2? subunit, in particular the ?2?-1 subunit, of the voltage-gated calcium channel, in particular having dual pharmacological activity towards both the ?2? subunit, in particular the ?2?-1 subunit, of the voltage-gated calcium channel and the ?-opioid receptor. The present invention also relates to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to new compounds of general formula (I) that show great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially ?2?-1 subunit of voltage-gated calcium channels or dual activity towards subunit ?2? of voltage-gated calcium channels (VGCC), especially ?2?-1 subunit of voltage-gated calcium channels, and noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to new compounds of general formula (I) that show great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially ?2?-1 subunit of voltage-gated calcium channels or dual activity towards subunit ?2? of voltage-gated calcium channels (VGCC), especially ?2?-1 subunit of voltage-gated calcium channels, and noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperidene compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperidene compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperidene compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.